课题基金 / 基金详情

RUI: MEF2 and Regulation of Transcription of the Skeletal Muscle Actin Gene

RUI: MEF2 and Regulation of Transcription of the Skeletal Muscle Actin Gene
RUI:MEF2 和骨骼肌肌动蛋白基因转录的调控
批准号:
9983140
负责人:
Sandra Sharp
金额:
$24.0万
依托单位国家:
美国
项目类别:
Continuing Grant
财政年份:
2000
资助国家:
美国
项目状态:
已结题
起止时间:
2000-02-01 至 2004-01-31

项目摘要

项目成果

Sandra Sharp的其他基金

相似基金

相关文献

中文摘要
翻译
肌肉发生的过程,即前体细胞发育成骨骼肌的过程,受到复杂的分子机制的相互作用的调节。了解这些机制的一种方法是研究DNA-蛋白质和蛋白质-蛋白质之间的相互作用,这些相互作用调节肌肉特异基因的转录。本项目将研究转录反式激活因子MEF2及其与DNA的结合在促进肌肉发生调控因子MyoD激活转录方面的作用。哺乳动物骨骼肌发生需要肌肉发生调节因子(MRF)和肌肉发生增强因子2(MEF2)家族的成员。MEF2由A-D四个不同的基因表达,形成同源和异源二聚体。不同异构体的细胞和启动子特异性作用尚不清楚,已知的是MRF和MEF2因子协同作用;也就是说,当MRF和MEF2都存在时,由LEST启动子驱动的转录得到更大程度的增强,而不是单独添加它们的影响。在人工测试启动子上,即使只有一个家族的结合位点存在,或者当MEF2或MRF缺乏反式激活结构域时,这种协同作用也可以发生。骨骼肌肌动蛋白(SKMA)基因的启动子不同于迄今检测到的MEF2/MRF协同作用的启动子,因为MEF2和MRF的结合部位不是彼此非常接近,而是彼此相距很远。最大效率的SKMA基因的表达需要MEF2结合位点的存在,然而,还不可能证明MEF2在MyoD激活SKMA启动子中的作用。相反,在相同的条件下,控制修饰的肌酸激酶(MCK)启动子由两个紧密间隔的MEF2和MyoD结合位点组成,很容易显示出协同作用。因此,MEF2对转录效率的贡献的各个方面仍有待解释。使用SKLAA、MCK和MEF2位点阴性启动子的瞬时转染和荧光素酶报告分析将用于验证以下假设。1)小鼠SKMA启动子的高效转录依赖于MEF2位点和超活性MEF2。2)MEF2的不同异构体或异二聚体对某一启动子的激活效力不同,同一异构体对所有启动子的作用也不尽相同。3)MEF2可通过反式激活和转录失活两种方式促进启动子的激活。这两个贡献的相对意义既是异构体的,也是启动子特异的。为了验证这些假说,将在非肌肉细胞中进行转基因,每个不同的启动子都有报告结构,Myo[)有一个表达结构,而MEF2亚型的表达结构以及MEF2活性的抑制和刺激因素将视情况而定。这些实验得出的结论将有助于我们理解基因表达是如何调控的。他们将允许建立更广泛的监管模型,然后可以通过进一步的实验进行测试,参与研究过程将有助于将本科生和硕士学位学生发展为科学家,并将激励学生继续攻读高级学位或进入劳动力大军,成为分子生物学的研究助理或社区大学教育工作者。
英文摘要
SharpThe process of myogenesis, by which precursor cells develop into skeletal muscle, is regulated by an intricate interplay of molecular mechanisms. One approach to understanding these mechanisms is to study the DNA-protein and protein-protein interactions that regulate transcription of muscle-specific genes. This project will investigate the role of the transcriptional transactivator MEF2 and its binding to DNA in facilitating the activation of transcription by the myogenesis regulatory factor MyoD. Members of both the myogenesis regulatory factor (MRF) and the myogenesis enhancing factor 2 (MEF2) families are required for skeletal myogenesis in mammals. MEF2s are expressed from four different genes, A-D, and form homo- and heterodimers. The cell- and promoter-specific roles of the different isoforms are not known, It is known that MRF and MEF2 factors act synergistically; that is, transcription driven by a lest promoter is enhanced to a greater extent when both a MRF and a MEF2 are present than can be explained by adding the effects of each of them alone. On artificial test promoters, this synergism can occur even when the binding site for only one family is present, or when either MEF2 or MRF lacks a transactivation domain. The promoter of the skeletal muscle actin (SKMA) gene differs from the promoters for which MEF2/MRF synergism has been tested thus far in that the binding sites for MEF2 and MRF, rather than being situated very near each other, are widely separated from each other. Maximum efficiency of expression of the SKMA gene requires the presence of a MEF2 binding site, However, it has not been possible to demonstrate a contribution of MEF2 to the activation of the SKMA promoter by MyoD using a transient transfection system in which MEF2 and MyoD are expressed from transgenes in non-muscle cells. In contrast, under the same conditions, synergism is easily demonstrable on a control modified muscle creatine kinase (MCK) promoter comprising two closely spaced MEF2 and MyoD binding sites. Thus aspects of the contribution of MEF2 to transcriptional efficiency remain to be explained. Transient transfection and luciferase reporter assays with SKLAA, MCK, and MEF2 site-negative promoters will be used to test the following hypotheses. 1) Efficient transcription from the mouse SKMA promoter is dependent upon the MEF2 site and upon transc6ptionally active MEF2. 2) Different isoforms or heterodimers of MEF2 have different potencies with respect to activation of a given promoter, and the contribution of a given isoform is not the same for all promoters. 3) MEF2 can contribute to promoter activation both through its transactivational activity and when it is inactive transcriptionally. The relative significance of the two contributions is both isoform and promoter specific. To test these hypotheses, transfections will be carried out in non-muscle cells with reporter constructs for each of the different promoters and an expression construct for Myo[), while inclusion of expression constructs for the MEF2 isoforms, as well as inhibitors and stimulators of MEF2 activity, will be varied as appropriate.The conclusions drawn from these experiments will contribute to our understanding of how gene expression is regulated. They will allow the construction of broader regulatory models that can then be tested by further experimentation, Involvement in the research process will contribute to the development of undergraduate and Masters Degree students as scientists and will motivate students to continue for advanced degrees or to enter the workforce as research associates or community college educators in molecular biology.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
RUI: DNA-Protein Interactions Regulating Transcription of the Skeletal Muscle Actin Gene
RUI: DNA - Protein Interactions Regulating Transcription of the Skeletal Muscle Actin Gene in Different Myogenic Milieu
CAA: DNA-Protein Interactions Regulating Transcription of the Id Protein Gene During Myogenesis
Gene Manipulation: A Practical Undergraduate Education in the Theory, Methods, and Potential of Biotechnology.
国内基金
海外基金
p300/miR-1281共转录本调控MEF2活性促发心肌肥大的作用机制研究
MEF2激活剂T-006对阿尔茨海默病的神经保护作用及机制研究
  • 批准号:
    --
  • 项目类别:
    面上项目
  • 资助金额:
    55万元
  • 批准年份:
    2021
  • 负责人:
    杨细飞
  • 依托单位:
PAK4通过MEF2/ZEB1促进内皮间质转化介导胶质母细胞瘤血管异常的机制研究
  • 批准号:
    82002628
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    24.0万元
  • 批准年份:
    2020
  • 负责人:
    马文娟
  • 依托单位:
钩藤碱及其类似物:增强MEF2转录活性对抗Aβ寡聚体神经毒性之分子机制研究
  • 批准号:
    2020A151501429
  • 项目类别:
    省市级项目
  • 资助金额:
    10.0万元
  • 批准年份:
    2020
  • 负责人:
    胡胜全
  • 依托单位: